ToolGen Inc
199800
Company Profile
Business description
ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.
Contact
KOR-collar Gasan Digital Valley 1 to 219 digital Byeoksan
6th 1204 No. ENG No. 1204, Byucksan Digital Valley 6-cha
219 Gasan Digital 1-ro, Geumcheon-gu
Seoul
KORT: +82 28738168
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
82
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,010.10 | 117.10 | -1.28% |
| CAC 40 | 7,721.61 | 67.36 | 0.88% |
| DAX 40 | 23,640.35 | 153.02 | 0.65% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,155.92 | 39.23 | 0.43% |
| HKSE | 25,343.43 | 153.12 | -0.60% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 41,938.89 | 371.60 | -0.88% |
| NZX 50 Index | 13,074.81 | 58.35 | -0.44% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,738.80 | 120.20 | -1.36% |
| SSE Composite Index | 3,813.56 | 44.58 | -1.16% |